HKSTP Ventures' Portfolio

Our Portfolio

HKSTP Ventures gives early-stage Hong Kong technology startups a chance to fully develop their ideas and create revolutionary new tech products and services.

At HKSTP, we want to turn creative inspirations into outstanding ideas.

And sometimes, our partner companies may simply have an initial concept.

However, a concept itself has the potential to change the world.

We recognised the need to foster and nurture these early-stage technology startups, so our local talent can have the opportunity to bring changes on a global scale.

Sector agnostic by nature, our fund’s current portfolio covers a broad spectrum of startups:

Biomedical Technology
  • Genomic Profiling
  • Drug Discovery
  • Drug Delivery
  • Surgical Robotics
Enterprise Solution
  • Education Platform
  • SaaS
Fintech
  • NLP Solution
Green Technology
  • Efficient battery
  • Non-toxic chemical
Logistics
  • Autonomous Driving
Semiconductor
  • Wearable Device
  • IC Design
Textile 4.0
  • New chemical

Selected Portfolio Companies

 

Volt14 Solutions is an advanced battery materials company, developing high capacity anode materials for Li-ion batteries. Volt14 Solutions lies between raw materials producers and battery cell producers in the battery industry value chain, where we develop novel materials optimized for use in lithium ion batteries for different verticals. By increasing the energy density of existing Li ion batteries, Volt14 will enable the next generation of consumer electronics and electric mobility.

 

ACT Genomics is an innovation-driven cancer solution provider in Asia with offices in Hong Kong, Taiwan, Singapore & Tokyo. With our Next-Generation Sequencing (NGS) technology and experienced bioinformatics team, we provide optimal cancer treatment planning, cancer relapse and drug resistance monitoring, cancer risk assessment and immunotherapy evaluation to medical professionals.

 

AutoX’s camera-first multi-sensor fusion system enables robust self-driving performance for the most challenging scenarios in urban driving. In Urban system is the first Al system in the world that could handle China’s metropolitan downtown driving scenarios. Partnered with multiple major automakers of the world. AutoX is on a path to build the world’s most experienced Al driver to enable mobility and logistics companies to enjoy the benefit of the most reliable self-driving technology.

 

Tinctorium focuses on synthetic biology that makes the world of colours more sustainable, without using petroleum and other toxic water-polluting chemicals in the process. It started with using engineered bacteria to make an indigo colourant for dyeing denim.

 

Belun® Technology specialises in digital health. Headquartered in Hong Kong, the company is formed of experts in compact sensing, biomedical signal processing and AI-based algorithms. Their technologies support tele-medicine, remote monitoring, pre-screening, management and risk analysis of chronic diseases, such as sleep, respiratory, psychiatric and cardiovascular disorders. Belun® also partners with medical professionals in sleep medicine, psychiatry and cardiology from several prestigious medical schools worldwide.

 

Opharmic Technology (formerly Sonikure Technology) has developed the MeticTouch device that can safely and efficiently deliver drugs into an eye via its patented low-energy and low-intensity ultrasonic technology. Compatible with injectable eye drugs, the device makes eye treatment injections non-invasive, painless, effective and proven complication-free in pre-clinical trials. It serves to replace the currently more commonly used, yet relatively more painful, needle injection method that could potentially induce a series of side effects.

 

Fano Labs specialises in applying Speech Recognition and Natural Language Processing technologies for smart recognition of languages and dialects, especially Cantonese and languages in Southeast Asia. Its solutions can enhance customer service quality by detecting and analysing the sentiment of the customers. They also help companies accurately identify potential compliance risks, reduce costs and deliver valuable business insights for uncovering potential sales opportunities.

 

Founded in 2000, Bio-Cancer Treatment Ltd is a clinical-stage biopharmaceutical company focusing on the research and development of innovative biologics for the treatment of human malignancies. Its drug candidate BCT-100, a pegylated recombinant human arginase, is currently being investigated in Phase II clinical trials in patients with acute myeloid leukemia (AML), prostate cancer and melanoma.

Contact Us

For general enquiry, or questions about HKSTP’s services and support, please enter your email address and query here.